(Q33265642)

English

Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 July 2017

Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine (English)

1 reference

Europe PubMed Central

24 July 2017

1 reference

based on heuristic

inferred from title

author name string

Jeannette Johansson

1

1 reference

Europe PubMed Central

24 July 2017

Lars Hellman

2

1 reference

Europe PubMed Central

24 July 2017

language of work or name

0 references

publication date

13 November 2006

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

24 July 2017

25

1 reference

Europe PubMed Central

24 July 2017

9

1 reference

Europe PubMed Central

24 July 2017

1676-1682

1 reference

Europe PubMed Central

24 July 2017

Identification of adjuvants that enhance the therapeutic antibody response to host IgE.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Generation of therapeutic antibody responses against IgE through vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Generation of therapeutic antibody responses against IgE in dogs, an animal species with exceptionally high plasma IgE levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Triggering TLR signaling in vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Use of CpG oligodeoxynucleotides as immune adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Virus-like particles as a modular system for novel vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Evidence for an early appearance of modern post-switch isotypes in mammalian evolution; cloning of IgE, IgG and IgA from the marsupial Monodelphis domestica

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Characterization and molecular cloning of the mRNA for the heavy (epsilon) chain of rat immunoglobulin E.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Properties of the extracellular calcium binding module of the proteoglycan testican

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Nidogen-2: a new basement membrane protein with diverse binding properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Cloning of IgE from the echidna (Tachyglossus aculeatus) and a comparative analysis of epsilon chains from all three extant mammalian lineages.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

A vaccine that prevents pregnancy in women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Therapeutic antibodies elicited by immunization against TNF-alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Phase I study of TNFα AutoVaccIne in Patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Cellular and genetic mechanisms of self tolerance and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Aluminium compounds for use in vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Vaccination with genetically engineered allergens prevents progression of allergic disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Vaccine engineering improved by hybrid technology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.055

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.10.055

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

24 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33265642&oldid=1576815571"